Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Tazbentetol in Amyotrophic Lateral Sclerosis: NCT06903286 Clinical Landscape Report 2026
28 September 2026
NCT06903286 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Kesonotide in Glioblastoma Multiforme: NCT06926075 Clinical Landscape Report 2026
28 September 2026
NCT06926075 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
STR-04 in Amyotrophic Lateral Sclerosis: NCT06910384 Clinical Landscape Report 2026
28 September 2026
NCT06910384 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CUE-102 in Recurrent Glioblastoma: NCT06917885 Clinical Landscape Report 2026
28 September 2026
NCT06917885 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rituximab Biosimilar (ODDIFACT) in Glioblastoma Multiforme: NCT06973096 Clinical Landscape Report 2026
28 September 2026
NCT06973096 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ERAS-801 in Glioblastoma Multiforme: NCT06934889 Clinical Landscape Report 2026
28 September 2026
NCT06934889 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sitagliptin Phosphate in Glioblastoma: NCT07003542 Clinical Landscape Report 2026
28 September 2026
NCT07003542 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fulvestrant in Hormone receptor positive breast cancer: NCT07029399 Clinical Landscape Report 2026
28 September 2026
NCT07029399 clinical landscape for Hormone receptor positive breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Temozolomide in Glioblastoma Multiforme: NCT06991101 Clinical Landscape Report 2026
28 September 2026
NCT06991101 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Ependymoma: NCT07031765 Clinical Landscape Report 2026
28 September 2026
NCT07031765 clinical landscape for Ependymoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fulvestrant in Ovarian Cancer: NCT07038369 Clinical Landscape Report 2026
28 September 2026
NCT07038369 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT07045311 Clinical Landscape Report 2026
28 September 2026
NCT07045311 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.